The lancet oncology

• Latest
• Best
• Search…

• The lancet oncology · Jun 2022

  Philippa Kibugu-Decuir-founder of Breast Cancer Initiative East Africa.

  no abstract available

  keep going… mark as read…

• The lancet oncology · Jun 2022

  Comment Letter

  Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply.

  no abstract available

  keep going… mark as read…

• The lancet oncology · Jun 2022

  Comment Letter

  The future of precise cancer chronotherapeutics.

  no abstract available

  read more… or not…

• The lancet oncology · Jun 2022

  Comment

  Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia.

  no abstract available

  explore further… or not…

• The lancet oncology · Jun 2022

  Randomized Controlled Trial

  Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

  Targeted time-limited treatment options are needed for patients with relapsed or refractory chronic lymphocytic leukaemia. The aim of this study was to investigate the efficacy of minimal residual disease (MRD)-guided, time-limited ibrutinib plus venetoclax treatment in this patient group. ⋯ AbbVie and Janssen.

  keep reading… mark as read…